Yokota Tomoya, Yukino Hiroki, Doi Mihoko, Ohori Hisatsugu
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.
The efficacy of entrectinib, a potent inhibitor of tropomyosin receptor kinases, c-ros oncogene 1, and anaplastic lymphoma kinase has been demonstrated in neurotrophic receptor tyrosine kinase fusion-positive pediatric and adult solid tumors. However, real-world data on entrectinib therapy for salivary gland malignancies are limited.
We describe a multicenter case series of four consecutive patients with ETV6-NTRK3 fusion-positive metastatic salivary secretory carcinoma (SSC) treated with entrectinib.
All patients had a prior history of systemic therapy with cytotoxic chemotherapy or immune checkpoint inhibitors. All patients achieved durable radiographic complete response. Adverse events included weight gain, dizziness, increase in creatine kinase level, and withdrawal pain, but were manageable by the interruption and dose reduction of entrectinib.
Durable complete response was achieved with entrectinib in patients with ETV6-NTRK3 fusion-positive metastatic SSC. The clinical benefit of entrectinib supports the importance of routine screening for NTRK gene fusion in patients with SSC.
恩曲替尼是一种有效的原肌球蛋白受体激酶、c-ros原癌基因1和间变性淋巴瘤激酶抑制剂，其疗效已在神经营养性受体酪氨酸激酶融合阳性的儿童和成人实体瘤中得到证实。然而，关于恩曲替尼治疗涎腺恶性肿瘤的真实世界数据有限。
我们描述了一个多中心病例系列，连续4例ETV6-NTRK3融合阳性转移性涎腺分泌癌（SSC）患者接受了恩曲替尼治疗。
所有患者既往均接受过细胞毒性化疗或免疫检查点抑制剂的全身治疗。所有患者均实现了持久的影像学完全缓解。不良事件包括体重增加、头晕、肌酸激酶水平升高和停药疼痛，但通过中断恩曲替尼治疗和减少剂量可控制。
恩曲替尼使ETV6-NTRK3融合阳性转移性SSC患者实现了持久的完全缓解。恩曲替尼的临床获益支持了对SSC患者常规筛查NTRK基因融合的重要性。
